<p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場收盤後發佈其 2026 年第一季度財報。分析師預計 Journey Medical 本季度每股收益為（$0.07），收入為 1547.30 萬美元。有興趣的人士可以在公司即將發佈的 2026 年第一季度財報頁面上找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 13 日東部時間下午 4:30。</p>
<p>獲取 <strong>Journey Medical</strong> 的提醒：</p>
<p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近一次發佈財報是在 2023 年 3 月 25 日。該公司報告本季度每股收益為（$0.04），超出分析師共識預期的（$0.06）$0.02。該公司本季度的收入為 1608 萬美元，而分析師預期為 1886 萬美元。Journey Medical 的淨利潤率為負的 18.48%，股本回報率為負的 46.40%。分析師平均預計 Journey Medical 在當前財年每股收益為$0，在下一個財年每股收益為$1。</p>
<h2>Journey Medical 股票上漲 1.2%</h2>
<p>納斯達克 DERM 的股票在星期三開盤價為$5.18。該公司的市值為 1.4157 億美元，市盈率為-11.02，貝塔值為 1.03。Journey Medical 的 52 周低點為$4.31，52 周高點為$9.56。該公司的債務與股本比率為 0.79，速動比率為 1.53，流動比率為 1.79。該公司的 50 日移動平均價格為$6.28，200 日移動平均價格為$7.41。</p>
<h2>機構資金流入與流出</h2>
<p>一些對沖基金和其他機構投資者最近調整了對該公司的持股。Jump Financial LLC 在第四季度將其在 Journey Medical 的持股比例提高了 46.1%。Jump Financial LLC 現在擁有 20,183 股該公司的股票，價值 156,000 美元，此前在此期間又收購了 6,373 股。美國銀行（Bank of America Corp DE）在第三季度將其在 Journey Medical 的持股比例提高了 421.0%。美國銀行現在擁有 21,537 股該公司的股票，價值 153,000 美元，此前在此期間又收購了 17,403 股。Marshall Wace LLP 在第四季度收購了 Journey Medical 的新頭寸，價值 150,000 美元。Occudo Quantitative Strategies LP 在第四季度將其在 Journey Medical 的持股比例提高了 22.3%。Occudo Quantitative Strategies LP 現在擁有 18,913 股該公司的股票，價值 146,000 美元，此前在此期間又收購了 3,443 股。最後，富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Journey Medical 的持股比例提高了 109.1%。富國銀行現在擁有 15,748 股該公司的股票，價值 121,000 美元，此前在此期間又收購了 8,215 股。機構投資者和對沖基金持有該公司 7.25% 的股票。</p>
<h2>分析師評級上調與下調</h2>
<p>一些券商最近對 DERM 發佈了報告。HC Wainwright 在 2023 年 3 月 26 日的研究報告中重申了 “買入” 評級，並對 Journey Medical 的股票設定了$13.00 的目標價。Weiss Ratings 在 2023 年 4 月 20 日的研究報告中重申了 Journey Medical 的 “賣出（d-）” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Journey Medical 目前的平均評級為 “持有”，平均目標價為$13.00。</p>
<p><strong>獲取我們最新的 DERM 研究報告</strong></p>
<h2>Journey Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Journey Medical Corp，總部位於新澤西州費爾菲爾德，是一家商業皮膚病學公司，專注於在美國收購、開發和營銷處方皮膚病學產品。自 2019 年成立以來，該公司建立了一個包括品牌和仿製藥的外用療法組合，旨在解決多種皮膚病，包括痤瘡、特應性皮炎、真菌感染和炎症性病變。</p>
<p>該公司的產品線包括抗生素/抗炎組合和基於皮質類固醇的配方，通過專有的凝膠、乳膏和泡沫載體進行遞送。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Journey Medical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Journey Medical 嗎？</h2>
<p>在你考慮 Journey Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Journey Medical 並不在名單上。</p>
<p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DERM

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

<p>Journey Medical（納斯達克代碼：DERM）將於 5 月 13 日公佈 2026 年第一季度財報，分析師預測每股虧損 0.07 美元，收入為 1547 萬美元。該公司此前報告了 2025 年第一季度每股虧損 0.04 美元，超出預期。Journey Medical 的股票上漲了 1.2%，目前價格為 5.18 美元，市值為 1.4157 億美元。機構投資者增加了持股，分析師的評級各不相同，平均目標價為 13.00 美元</p>

<p>Journey Medical (NASDAQ:DERM - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Journey Medical to post earnings of ($0.07) per share and revenue of $15.4730 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.</p>
<div class="lb-trans"><p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場收盤後發佈其 2026 年第一季度財報。分析師預計 Journey Medical 本季度每股收益為（$0.07），收入為 1547.30 萬美元。有興趣的人士可以在公司即將發佈的 2026 年第一季度財報頁面上找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 13 日東部時間下午 4:30。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Journey Medical</strong> 的提醒：</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%. On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近一次發佈財報是在 2023 年 3 月 25 日。該公司報告本季度每股收益為（$0.04），超出分析師共識預期的（$0.06）$0.02。該公司本季度的收入為 1608 萬美元，而分析師預期為 1886 萬美元。Journey Medical 的淨利潤率為負的 18.48%，股本回報率為負的 46.40%。分析師平均預計 Journey Medical 在當前財年每股收益為$0，在下一個財年每股收益為$1。</p>
</div><h2>Journey Medical Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Journey Medical 股票上漲 1.2%</h2>
</div><p>Shares of NASDAQ DERM opened at $5.18 on Wednesday. The company has a market capitalization of $141.57 million, a P/E ratio of -11.02 and a beta of 1.03. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.53 and a current ratio of 1.79. The company's 50 day moving average price is $6.28 and its 200-day moving average price is $7.41.</p>
<div class="lb-trans"><p>納斯達克 DERM 的股票在星期三開盤價為$5.18。該公司的市值為 1.4157 億美元，市盈率為-11.02，貝塔值為 1.03。Journey Medical 的 52 周低點為$4.31，52 周高點為$9.56。該公司的債務與股本比率為 0.79，速動比率為 1.53，流動比率為 1.79。該公司的 50 日移動平均價格為$6.28，200 日移動平均價格為$7.41。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC lifted its position in shares of Journey Medical by 46.1% during the 4th quarter. Jump Financial LLC now owns 20,183 shares of the company's stock valued at $156,000 after acquiring an additional 6,373 shares during the period. Bank of America Corp DE lifted its position in shares of Journey Medical by 421.0% during the 3rd quarter. Bank of America Corp DE now owns 21,537 shares of the company's stock valued at $153,000 after acquiring an additional 17,403 shares during the period. Marshall Wace LLP acquired a new position in shares of Journey Medical during the 4th quarter valued at $150,000. Occudo Quantitative Strategies LP lifted its position in shares of Journey Medical by 22.3% during the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company's stock valued at $146,000 after acquiring an additional 3,443 shares during the period. Finally, Wells Fargo &amp; Company MN lifted its position in shares of Journey Medical by 109.1% during the 4th quarter. Wells Fargo &amp; Company MN now owns 15,748 shares of the company's stock valued at $121,000 after acquiring an additional 8,215 shares during the period. Institutional investors and hedge funds own 7.25% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近調整了對該公司的持股。Jump Financial LLC 在第四季度將其在 Journey Medical 的持股比例提高了 46.1%。Jump Financial LLC 現在擁有 20,183 股該公司的股票，價值 156,000 美元，此前在此期間又收購了 6,373 股。美國銀行（Bank of America Corp DE）在第三季度將其在 Journey Medical 的持股比例提高了 421.0%。美國銀行現在擁有 21,537 股該公司的股票，價值 153,000 美元，此前在此期間又收購了 17,403 股。Marshall Wace LLP 在第四季度收購了 Journey Medical 的新頭寸，價值 150,000 美元。Occudo Quantitative Strategies LP 在第四季度將其在 Journey Medical 的持股比例提高了 22.3%。Occudo Quantitative Strategies LP 現在擁有 18,913 股該公司的股票，價值 146,000 美元，此前在此期間又收購了 3,443 股。最後，富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Journey Medical 的持股比例提高了 109.1%。富國銀行現在擁有 15,748 股該公司的股票，價值 121,000 美元，此前在此期間又收購了 8,215 股。機構投資者和對沖基金持有該公司 7.25% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of brokerages have recently issued reports on DERM. HC Wainwright restated a &#34;buy&#34; rating and issued a $13.00 price target on shares of Journey Medical in a research report on Thursday, March 26th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Journey Medical currently has an average rating of &#34;Hold&#34; and an average price target of $13.00.</p>
<div class="lb-trans"><p>一些券商最近對 DERM 發佈了報告。HC Wainwright 在 2023 年 3 月 26 日的研究報告中重申了 “買入” 評級，並對 Journey Medical 的股票設定了$13.00 的目標價。Weiss Ratings 在 2023 年 4 月 20 日的研究報告中重申了 Journey Medical 的 “賣出（d-）” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Journey Medical 目前的平均評級為 “持有”，平均目標價為$13.00。</p>
</div><p><strong>Get Our Latest Research Report on DERM</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 DERM 研究報告</strong></p>
</div><h2>Journey Medical Company Profile</h2>
<div class="lb-trans"><h2>Journey Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.</p>
<div class="lb-trans"><p>Journey Medical Corp，總部位於新澤西州費爾菲爾德，是一家商業皮膚病學公司，專注於在美國收購、開發和營銷處方皮膚病學產品。自 2019 年成立以來，該公司建立了一個包括品牌和仿製藥的外用療法組合，旨在解決多種皮膚病，包括痤瘡、特應性皮炎、真菌感染和炎症性病變。</p>
</div><p>The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.</p>
<div class="lb-trans"><p>該公司的產品線包括抗生素/抗炎組合和基於皮質類固醇的配方，通過專有的凝膠、乳膏和泡沫載體進行遞送。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Journey Medical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Journey Medical 嗎？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Journey Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Journey Medical 並不在名單上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Journey Medical (DERM) 預計將在週三公佈財報